Research programme: anti-infectives - EPIRUS Biopharmaceuticals

Drug Profile

Research programme: anti-infectives - EPIRUS Biopharmaceuticals

Alternative Names: CRx-808

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CombinatoRx
  • Developer EPIRUS Biopharmaceuticals; National Institute of Allergy and Infectious Diseases; United States Army Medical Research Institute of Infectious Diseases
  • Class Small molecules
  • Mechanism of Action Anthrax toxin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alphavirus infections; Anthrax; Ebola virus infections; Hepatitis B; Hepatitis C

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 17 Jul 2014 No development reported - Preclinical for Alphavirus Infections in USA (unspecified route)
  • 17 Jul 2014 No development reported - Preclinical for Anthrax in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top